StockNews.com Initiates Coverage on Enzo Biochem (NYSE:ENZ)

Analysts at StockNews.com initiated coverage on shares of Enzo Biochem (NYSE:ENZ) in a report issued on Sunday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

Shares of NYSE:ENZ opened at $0.65 on Friday. The company’s fifty day moving average is $0.83 and its two-hundred day moving average is $1.02. Enzo Biochem has a 12-month low of $0.63 and a 12-month high of $1.40.

Enzo Biochem (NYSE:ENZ) last announced its quarterly earnings data on Monday, December 16th. The medical research company reported ($0.05) earnings per share (EPS) for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC grew its position in Enzo Biochem by 3.3% in the third quarter. Geode Capital Management LLC now owns 368,646 shares of the medical research company’s stock worth $413,000 after acquiring an additional 11,742 shares in the last quarter. BBR Partners LLC bought a new position in shares of Enzo Biochem in the 3rd quarter valued at approximately $112,000. XTX Topco Ltd lifted its holdings in Enzo Biochem by 94.5% in the 2nd quarter. XTX Topco Ltd now owns 28,262 shares of the medical research company’s stock worth $31,000 after purchasing an additional 13,735 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in Enzo Biochem by 2.6% during the second quarter. Renaissance Technologies LLC now owns 2,499,546 shares of the medical research company’s stock worth $2,725,000 after purchasing an additional 64,417 shares during the period. Hedge funds and other institutional investors own 36.90% of the company’s stock.

Enzo Biochem Company Profile

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.